Advancing HPV Vaccination Research: How Biospecimens Are Accelerating Progress Toward Cervical Cancer Elimination

Photo credit: CDC/ Robert Denty; James Gathany

Human papillomavirus (HPV) represents one of the most common sexually transmitted infections globally, with nearly all sexually active individuals encountering at least one HPV type during their lifetime. While most HPV infections resolve spontaneously, persistent infection with high-risk oncogenic strains — particularly HPV types 16 and 18 — causes virtually all cases of cervical cancer and contributes to cancers of the oropharynx, anus, vulva, vagina, and penis.^1,2 The development of prophylactic HPV vaccines represents one of modern medicine’s most significant cancer prevention achievements, with potential to eliminate cervical cancer as a public health threat within this century. HPV research sits at the intersection of our infectious disease and oncology biospecimen portfolios.

Research advancing HPV vaccination strategies relies fundamentally on access to well-characterized biospecimens from individuals with confirmed HPV infection across diverse viral types, vaccination statuses, and clinical outcomes. From study design to receipt of samples, investigators require specimens paired with comprehensive HPV genotyping data, antibody titers, vaccination history, and natural history information to evaluate vaccine efficacy, optimize dosing strategies, understand immune responses, and develop next-generation vaccines targeting additional HPV types.³

The World Health Organization’s endorsement of single-dose HPV vaccination schedules underscores the dynamic nature of this research field and the critical role biospecimens play in evidence generation supporting policy changes with global impact.⁴

Understanding HPV: Virology, Epidemiology, and Cancer Risk

HPV comprises over 200 viral types, classified as low-risk or high-risk based on oncogenic potential. Low-risk types such as HPV 6 and 11 cause benign conditions including genital warts, while high-risk types — most notably HPV 16 and 18 — account for approximately 70% of cervical cancer cases worldwide.⁵ Other high-risk types including HPV 31, 33, 35, 45, 52, and 58 contribute to the remaining cases.

Epidemiology and Disease Burden

• Global Prevalence: HPV infection affects an estimated 80% of sexually active individuals at some point in their lives, with peak prevalence in young adults shortly after sexual debut. Most infections clear within 1–2 years through natural immune responses.⁶
• Cancer Incidence: Cervical cancer ranks as the fourth most common cancer in women globally, with over 600,000 new cases and 340,000 deaths annually. Incidence varies dramatically by geography, with highest burdens in regions with limited screening and vaccination access.⁷
• Other HPV-Associated Cancers: Beyond cervical cancer, HPV causes substantial proportions of oropharyngeal cancers (particularly in men), anal cancers, and cancers of the vulva, vagina, and penis. Rising HPV-associated oropharyngeal cancer incidence in some populations highlights the importance of gender-neutral vaccination strategies.⁸

HPV Vaccines: Development, Implementation, and Impact

Three prophylactic HPV vaccines have received regulatory approval:

• Bivalent vaccine (HPV 16, 18)
• Quadrivalent vaccine (HPV 6, 11, 16, 18)
• Nonavalent vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58)

These vaccines utilize virus-like particles (VLPs) that mimic HPV capsid proteins, triggering robust antibody responses without infectious viral components. Clinical trials demonstrated efficacy exceeding 90% in preventing persistent infection and precancerous lesions caused by vaccine-included HPV types in previously uninfected individuals.^9,10

Global Implementation Progress

Since vaccine introduction in 2006, HPV vaccination programs have expanded to over 125 countries. Real-world evidence from countries with high vaccination coverage — including Australia, Scotland, and England — demonstrates dramatic reductions in HPV prevalence, genital warts, and cervical precancerous lesions, with early signals suggesting decreased cervical cancer incidence in vaccinated cohorts.^11,12

However, global vaccination coverage remains suboptimal, with particularly low uptake in low- and middle-income countries where cervical cancer burden is highest. The WHO recommendation supporting single-dose HPV vaccination schedules in girls ages 9–20 years represents a critical policy shift aimed at improving access and coverage.¹³

The Role of Biospecimens in HPV Vaccination Research

Well-characterized HPV biospecimens enable multiple critical research applications, including vaccine efficacy and effectiveness studies, immunogenicity assessment, natural history studies, and development of screening and diagnostics.

Vaccine Efficacy and Effectiveness Studies

Immunogenicity Assessment

Serum specimens from vaccinated individuals enable quantification of anti-HPV antibody titers against vaccine-included and non-included HPV types. Longitudinal collections track antibody persistence over years to decades, informing decisions about booster dose requirements. Studies comparing antibody responses after one, two, or three vaccination doses support evidence-based schedule optimization.¹⁴

Cross-Protection Evaluation

HPV vaccines demonstrate partial cross-protection against phylogenetically related non-vaccine HPV types. Biospecimens paired with comprehensive HPV genotyping enable assessment of cross-protection magnitude and duration, potentially expanding vaccine benefits beyond included types.

Breakthrough Infection Investigation

Although rare, confirmed HPV infections with vaccine-type strains can occur in vaccinated individuals. Investigating these breakthrough cases requires rapid access to specimens for viral genotyping, antibody measurement, and host immune characterization to understand potential failure mechanisms.

HPV Natural History and Immune Response Studies

Clearance vs. Persistence

Understanding why some confirmed HPV infections clear spontaneously while others persist and progress to cancer requires longitudinal specimen collections from individuals across disease stages. PBMC specimens enable characterization of HPV-specific cellular immunity, including T-cell and innate immune responses associated with viral clearance and persistence.¹⁵

Biomarker Discovery

Identifying biomarkers that predict persistence, precancerous progression, or treatment response requires specimens from individuals at multiple timepoints in HPV natural history. Candidate markers include HPV viral load in cervical specimens, HPV E6/E7 oncoprotein expression, methylation patterns, and host immune signatures. Complementing these signals with clinical covariates and genomic annotation can strengthen biomarker performance and interpretability across populations in the United States.

Co-Factor Investigation

Research exploring co-factors influencing HPV-related cancer risk — including smoking, immunosuppression, co-infections, and genetic susceptibility — requires biospecimens with detailed covariate documentation and standardized patient data capture. Integrated patient data annotation supports multivariable analyses that disentangle viral and host contributors to progression risk.

Screening and Diagnostics Development

HPV DNA Testing Validation

Commercial HPV DNA tests require validation using specimens confirmed for HPV status through multiple methods. Panels spanning HPV types, viral loads, and collection methods support assay development and regulatory submissions.

Novel Biomarker Validation

Emerging diagnostic approaches targeting HPV RNA, methylation biomarkers, or protein markers require well-characterized specimen sets for analytical and clinical validation. Access to specimens from acute infection through invasive cancer enables comprehensive test performance assessment.

Point-of-Care Test Development

Developing rapid HPV tests for use in underserved settings requires specimens representative of target populations, including self-collected vaginal samples and specimens from individuals with varying infection prevalences.

Single-Dose HPV Vaccination: Research Supporting Policy Change

The WHO endorsement of single-dose HPV vaccination schedules represents a paradigm shift based on accumulating evidence from clinical trials and real-world implementation studies. This policy change has profound implications for global cervical cancer elimination efforts, potentially improving coverage while reducing costs and logistical challenges.¹⁶

Evidence Base for Single-Dose Schedules

Immunogenicity Data

Studies utilizing biospecimens from single-dose vaccine recipients demonstrated high and sustained antibody titers at levels predicted to provide protection. While antibody concentrations were lower than after multi-dose schedules, they exceeded natural infection levels and remained stable over extended follow-up periods.¹⁷ These studies often rely on standardized serum and plasma collections to enable consistent serology testing across platforms and timepoints.

Effectiveness Evidence

Real-world data from settings where programmatic challenges led to single-dose receipt for many individuals showed substantial reductions in HPV infection rates and cervical precancerous lesions. These findings, enabled by population-based specimen collection and HPV testing, provided critical evidence supporting policy changes.¹⁸

Duration of Protection

Longitudinal biospecimen collections tracking antibody persistence over 10+ years post-single-dose vaccination inform modeling studies predicting long-term protection. Continued monitoring through biospecimen-based surveillance will validate long-term effectiveness assumptions.

Biospecimen Requirements for HPV Research

Sample Types and Annotation

Cervical and Vaginal Specimens

Clinician-collected or self-collected cervical/vaginal samples in appropriate transport media enable HPV genotyping, viral load quantification, and co-testing strategies. Specimens should be paired with cytology results and colposcopy findings when available.

Serum and Plasma

High-quality serum collected using standardized protocols enables antibody testing across multiple HPV types. Plasma can support complementary immunologic assays and multi-analyte biomarker work, with scalable programs sometimes leveraging bulk plasma for assay development, validation panels, and inter-lab harmonization.

Peripheral Blood Mononuclear Cells

Cryopreserved PBMCs from vaccinated and HPV-infected individuals support cellular immunity studies, including HPV-specific T-cell responses and innate immune characterization. Where deeper immune phenotyping is required, immune subsets such as CD3+ T cells and CD56+ NK cells can enable mechanistic studies of immune correlates of protection.

Tissue Specimens

When available, cervical tissue biopsies or surgical specimens from precancerous lesions or invasive cancers enable investigation of local immune responses, viral integration patterns, and host-pathogen interactions.

Critical Clinical Annotation

Specimens should include comprehensive documentation of:

HPV Testing Results

• HPV genotype(s) detected
• Viral load or cycle threshold values
• Testing methodology and platform
• Specimen collection date and anatomic site

Vaccination History

• Vaccine product (bivalent, quadrivalent, or nonavalent)
• Number of doses received and dates
• Age at first vaccination
• Reasons for incomplete series (if applicable)

Clinical Outcomes

• Cervical cytology results (Pap test findings)
• Colposcopy and biopsy findings
• Treatment interventions for precancerous lesions
• Natural history outcomes (clearance vs. persistence)

Demographics and Risk Factors

• Age, race/ethnicity, geographic location
• Sexual behavior history (as collected/approved by protocol)
• Smoking status
• Immunosuppression status
• Co-infections (HIV, other STIs)

Emerging Research Frontiers in HPV Prevention

Therapeutic Vaccines

While prophylactic HPV vaccines prevent new infections, they do not treat existing confirmed HPV infections or established lesions. Therapeutic vaccine development targeting HPV-infected cells and precancerous lesions requires specimens from individuals with documented persistent HPV infection and cervical dysplasia.¹⁹

Gender-Neutral Vaccination Strategies

HPV-associated cancers in men — particularly oropharyngeal cancers — have driven expansion of vaccination recommendations to include boys. Research evaluating vaccine impact in male populations benefits from well-characterized specimens from men across populations in the United States, paired with vaccination history and confirmed HPV status.

Immunocompromised Populations

Individuals with HIV, organ transplants, or other immunocompromising conditions face elevated HPV-related cancer risks and may respond differently to vaccination. Studies in these populations require carefully characterized specimens with detailed immunologic annotation.

Next-Generation Vaccines

Development of vaccines targeting additional HPV types, utilizing novel platforms, or incorporating therapeutic components requires diverse biospecimen resources for proof-of-concept and clinical validation studies.

Supporting Global Cervical Cancer Elimination

The WHO has set ambitious targets for cervical cancer elimination: 90% of girls vaccinated by age 15, 70% of women screened with high-performance tests, and 90% of women with cervical disease receiving treatment. Achieving these goals requires sustained research enabled by robust biospecimen resources.

Sanguine supports HPV research through our infectious disease biospecimen portfolio and oncology biospecimen portfolio, available via inventory and prospective collection services. Custom cohorts can be designed to match specific HPV types, vaccination statuses, disease stages, and demographic characteristics across populations in the United States.

From study design to receipt of samples, streamlined processes help research timelines stay on track while delivering specimens meeting specifications for genotyping, serology, and advanced data requirements — including linkable genomic annotation where appropriate.

Real-World Impact: Biospecimens Driving Policy and Practice

The shift from three-dose to single-dose HPV vaccination schedules illustrates how biospecimen-based research influences public health policy with global impact. This evidence pathway — from controlled clinical trials through real-world effectiveness studies — required specimen collection, testing, and analysis across multiple countries and populations.

Similarly, progression from HPV DNA testing as an adjunct to cytology screening toward primary HPV screening strategies relied on biospecimen-based validation studies demonstrating improved sensitivity for detecting precancerous lesions. These policy changes promise to accelerate cervical cancer elimination through more effective screening approaches.

Future policy decisions — including expansion of single-dose vaccination in additional groups, optimization of screening intervals, and adoption of self-collection strategies — will continue to depend on rigorous biospecimen-based research.

Conclusion

HPV vaccination and screening represent powerful tools for cervical cancer elimination, with potential to prevent hundreds of thousands of cancer deaths globally each year. The research driving continued optimization of these interventions — from single-dose vaccination schedules to next-generation vaccines and novel diagnostics — relies fundamentally on access to well-characterized biospecimens.

HPV biospecimen collections with comprehensive genotyping, serology, and clinical annotation enable investigators to evaluate vaccine performance, understand HPV natural history, validate diagnostic tests, and develop prevention strategies. As the global community works toward cervical cancer elimination, continued investment in HPV biospecimen resources will remain essential to achieving this public health goal.

---

References

1. de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664-670. doi:10.1002/ijc.30716
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. doi:10.3322/caac.21492
3. Schiller JT, Lowy DR. Raising expectations for subunit vaccine. J Infect Dis. 2015;211(9):1373-1375. doi:10.1093/infdis/jiu648
4. WHO. WHO Looks Back at 2024 – Vaccine Introductions. World Health Organization. Published 2024. Accessed December 9, 2024.
5. Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518-527. doi:10.1056/NEJMoa021641
6. Chesson HW, Dunne EF, Hariri S, Markowitz LE. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis. 2014;41(11):660-664. doi:10.1097/OLQ.0000000000000193
7. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660
8. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29(32):4294-4301. doi:10.1200/JCO.2011.36.4596
9. Paavonen J, Naud P, Salmerón J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301-314. doi:10.1016/S0140-6736(09)61248-4
10. Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711-723. doi:10.1056/NEJMoa1405044
11. Falcaro M, Castañon A, Ndlela B, et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet. 2021;398(10316):2084-2092. doi:10.1016/S0140-6736(21)02178-4
12. Lei J, Ploner A, Elfström KM, et al. HPV Vaccination and the Risk of Invasive Cervical Cancer. N Engl J Med. 2020;383(14):1340-1348. doi:10.1056/NEJMoa1917338
13. Barnabas RV, Brown ER, Onono MA, et al. Efficacy of Single-Dose HPV Vaccination among Young African Women. NEJM Evid. 2022;1(5). doi:10.1056/EVIDoa2100056
14. Kreimer AR, Struyf F, Del Rosario-Raymundo MR, et al. Efficacy of Fewer Than Three Doses of an HPV-16/18 AS04-Adjuvanted Vaccine: Combined Analysis of Data From the Costa Rica Vaccine and PATRICIA Trials. Lancet Oncol. 2015;16(7):775-786. doi:10.1016/S1470-2045(15)00047-9
15. Stanley MA. Epithelial cell responses to infection with human papillomavirus. Clin Microbiol Rev. 2012;25(2):215-222. doi:10.1128/CMR.05028-11
16. Basu P, Malvi SG, Joshi S, et al. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study. Lancet Oncol. 2021;22(11):1518-1529. doi:10.1016/S1470-2045(21)00453-8
17. Sankaranarayanan R, Prabhu PR, Pawlita M, et al. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. Lancet Oncol. 2016;17(1):67-77. doi:10.1016/S1470-2045(15)00414-3
18. WHO. One-dose Human Papillomavirus (HPV) Vaccine Offers Solid Protection Against Cervical Cancer. World Health Organization. Published April 11, 2022. Accessed December 9, 2024.
19. Yang A, Farmer E, Wu TC, Hung CF. Perspectives for therapeutic HPV vaccine development. J Biomed Sci. 2016;23(1):75. doi:10.1186/s12929-016-0293-9